insight grants are expected to respond to the objectives of the insight program.

insight grants support research excellence in the social sciences and humanities. funding is available to both emerging and established scholars for research initiatives of two to five years.

stable support for long-term research initiatives is central to advancing knowledge. it enables scholars to address complex issues about individuals and societies, and to further our collective understanding.

insight grants support research proposed by scholars and judged worthy of funding by their peers and/or other experts. insight grant research initiatives can be undertaken by an individual researcher or a team of researchers working in collaboration.

applicants choose from one of two streams, depending on the amount of funding required. both streams will be adjudicated by the same committees, and will receive the same rigorous level of merit review. the deadlines and application process are identical for both; however, the targeted success rate for stream a is higher than for stream b.

sshrc welcomes applications involving indigenous research, as well as those involving research-creation.

ontario genomics is pleased to announce that genome canada’s genomic applications partnership program (gapp) is now open for applications.

the gapp funds public-private research collaborations focused on validating genomics-derived technologies that address opportunities and challenges identified by industry, government, not-for-profits or other “receptors” of genomics knowledge and tools across all sectors. the program provides a unique opportunity for receptor organizations to collaborate with an ’omics researcher, and to leverage their r&d investments with public funding.

key program highlights:

• budget: $300k - $6m (total)
• co-funding: 1/3 genome canada (max), 1/3 receptor (min), up to 1/3 other, as applicable
• award duration: 2 - 3 years
• stage: downstream r&d/validation/pilot
• funding recipient: genome canada award flows to academic partner only

to apply:
please contact ann meyer, advisor, sector innovation & programs, to discuss the fit of potential projects with the program and key criteria for gapp. project teams that are a potential fit will be provided the expression of interest (eoi) form. please refer to our website for deadlines of other upcoming gapp rounds.

learn more:

• genomic applications partnership program (gapp)
• previously funded gapp projects

the endgame leader student leadership grant provides a stipend for leaders who are interested in working closely and collaboratively with the ohtn to drive change, contribute to rapid learning and improvement in our sector, and build hiv innovation capacity in ontario. the student leadership grant is for excellent phd 世界杯2022赛程表淘汰赛 who are working with ohtn-funded leaders or other ontario-based hiv investigators, and who have the potential to become hiv leaders. their work should explore gaps in, identify barriers to, or identify facilitators of effective hiv prevention, treatment, and care in ontario, and collaborate with a population with whom the student’s mentor also has strong ties.

cmc is accepting nominations for the 2021 douglas r. colton medal for research excellence.  

this award includes a monetary prize of $4,500 and recognizes excellence in:

• research leading to new understanding and novel developments in one or more microsystems or nanotechnologies such as photonics/optoelectronics, microelectromechanical systems (mems), nanoelectronics, microelectronics, microfluidics and embedded software; and/or
• the application of microsystems and/or nanotechnology in canada.

the deadline for nominations is friday, august 27, 2021.  candidates for the award must be nominated by:

• university research offices; or
• companies in microsystems or nanotechnology and/or related sectors in canada; or
• jointly by a university and a company.

any post-secondary institution eligible for support by the natural sciences and engineering research council (nserc) or any microsystems-related company in canada may nominate one person per year. 

an announcement has been made to research offices and members of industry across canada’s national design network. to learn more about the award, including eligibility requirements and nomination guidelines, please visit www.cmc.ca/awards.

the presentation of the douglas r. colton medal for research excellence will take place in the fall.

if you are interested in being nominated for this award, please contact dr. batia stolar, associate vice-president, research & graduate studies, at avp.research@lakeheadu.ca

the fy21 defense appropriations act provides funding to the department of defense alcohol and substance abuse disorder research program (asadrp) to support research of exceptional scientific merit in the area of alcohol, opioid, and other substance use disorders research.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the asadrp is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated fy21 funding opportunity.  this pre-announcement should not be construed as an obligation by the government.  the fy21 asadrp program announcement and general application instructions for the following award mechanism will be posted on the grants.gov website.  pre-application and application deadlines will be available when the program announcements are released. 

consortium award applications submitted to the fy21 asadrp should address how the consortium will conduct multidisciplinary, team-based translational research efforts to identify promising compounds; conduct proof-of-principle basic research and conduct human proof-of-concept trials with promising compounds to address effective treatments for alcohol and substance use disorders (asud), to include reducing the overall number of opioid-related overdose deaths.

areas of emphasis:  the consortium is encouraged to address these areas of emphasis in order to reduce the overall number of opioid-related overdose deaths.

• improved formulations to treat opioid use disorder with comorbid substance use
• improved formulations to treat opioid use disorders with comorbid post-traumatic stress disorder (ptsd) and other psychological disorders
• new formulations and/or combinations of existing medications to improve treatment compliance, prevent relapse, and reduce risk of misuse
• stronger, longer-duration formulations to counteract opioid (including fentanyl analogs) overdose
• novel medications and immunotherapies to treat substance and/or alcohol use disorders
• new medication targets for the treatment of substance and/or alcohol use disorders

the overall strategy of the asadrp supports the following research aims:

aim 1 ‒ discover:  testing new chemical entities and repurposing existing medications in preclinical and non-clinical models of asud with comorbid ptsd and other psychological disorders.

aim 2 ‒ proof of concept:  human studies of potential medications that include assessment of medical safety and doses for potential efficacy in subjects with asud and comorbid ptsd and other psychological disorders.

aim 3 ‒ phase ii safety and preliminary efficacy:  multiple site clinical trials to test potential medications or medication combinations in humans with asud and comorbid ptsd and other psychological disorders, and to also explore precision medicine tools for matching patients to these medications.

https://cdmrp.army.mil/funding/asadrp

consortium award – letter of intent due august 18, 201

• independent intramural (dod) and extramural investigators at all academic levels (or equivalent).
• supports a consortium to identify promising compounds; conduct proof-of-principle basic research and conduct human proof-of-concept trials with promising compounds to address effective treatments for alcohol and substance use disorders, to include reducing the overall number of opioid-related overdose death.

the consortium will consist of a single management core as well as basic research and clinical trial sites.

• the maximum period of performance is 5 years.
• the cdmrp expects to allocate fy21-23 funding, if appropriated, to fund approximately one asadrp consortium award.
• the asadrp consortium will be funded initially with allocations from the fy21 asadrp congressional appropriation ($3.525m).
• the maximum allowable total costs (direct and indirect) for the entire period of performance are $10.575m (initial period of performance plus 2 options).
• two additional options, to be included in the application, may be funded from allocations from the fy22 and fy23 congressional appropriation (up to $3.525m each year) subject to programmatic panel review, approval of the grants officer, and receipt of future congressional appropriations.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the asadrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk

301-682-5507

help@ebrap.org

the fy21 defense appropriations act provides funding to the department of defense kidney cancer research program (kcrp) to support research of exceptional scientific merit in the area of kidney cancer.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the kcrp is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated fy21 funding opportunities.  this pre-announcement should not be construed as an obligation by the government.  the fy21 kcrp program announcements and general application instructions for the following award mechanisms will be posted on the grants.gov website.  pre-application and application deadlines will be available when the program announcements are released. 

applications submitted to the fy21 kcrp must address one or more of the following focus areas:

• conduct basic biology research to better understand etiology and cancer progression, metastatic disease, refractory disease and therapeutic resistance, genetic and environmental risk factors and the prevention of kidney cancer.
• identify and develop new strategies for screening, early-stage detection, accurate diagnosis and prognosis prediction of kidney cancers, with examples including biomarkers and imaging.
• define the biology of rare kidney cancers and develop treatments to improve outcomes and reduce death.
• develop novel therapeutic strategies for the treatment of kidney cancer, such as novel drug targets, therapeutic modalities and agents, treatment combinations and drug delivery systems.
• identify and implement strategies to improve the quality of life of patients.
• identify and implement strategies to mitigate health disparities, such as access to healthcare, social and cultural factors, environmental factors, and biological contributors.

https://cdmrp.army.mil/funding/kcrp

academy of kidney cancer investigators – early-career investigator award – letter of intent due september 14, 2021

within 3 years of last postdoctoral research position (ph.d.) or clinical fellowship (m.d.), or equivalent, as of full application submission deadline.

letter attesting to eligibility required.

• supports addition of new early-career investigators (ecis) to the unique, interactive virtual academy providing intensive mentoring, national networking, and a peer group for junior faculty.
• ecis whose ability to commit to conducting kidney cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply.
• a designated mentor who is an experienced kidney cancer researcher with a record of kidney cancer funding is required.
• the designated mentor not required to be at the same institution as the eci.
• preliminary data required.
• clinical trials are not allowed.
• maximum funding of $725,000 for direct costs (plus indirect costs).
• maximum period of performance 4 years.
• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

clinical trial award – letter of intent due september 14, 2021

independent investigators at all levels.

• supports projects ranging from small proof-of-concept trials (e.g., pilot, first in human, phase 0) to demonstrate feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations.
• clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies.
• investigational new drug (ind) or investigational device exemption (ide) application, if applicable, must be submitted to the u.s. department of food and drug administration (fda) by the time of application submission.
• documented availability of and access to the drug/compound, device, and/or other materials needed, as appropriate, for the proposed duration of the study must be provided.
• clinical trials are expected to begin no later than 12 months after the award date, or 18 months after the award date for fda-regulated studies.
• maximum funding of $2,000,000 for direct costs (plus indirect costs).
• maximum period of performance is 4 years.
• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

clinical research nurse development award – letter of intent due september 14, 2021

the initiating principal investigator (pi) must be at or above the level of assistant professor (or equivalent) with an m.d. and/or m.d./ph.d. degree (or equivalent).

• the partnering pi must be a clinical research nurse coordinator with at least 2 years of oncology or cancer clinical trial research nurse experience, and have a registered nurse license and/or a bachelor’s, master’s, or doctoral degree in nursing.
• supports partnerships between a clinician and a clinical research nurse coordinator (or equivalent).
• supports kidney cancer research and the career development of kidney cancer clinical trial research nurses.
• clinical trials are not allowed; correlative studies to clinical trials are allowed.
• maximum funding of $300,000 for direct costs (plus indirect costs).
• maximum period of performance is 2 years.
• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions that will be available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

submission deadlines are not available until the program announcements are released.  for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the kcrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp public affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

throughout the canadian forest sector, lignin has traditionally been treated as low-quality, low-value side streams of product processing. however, lignin is an abundant raw material. when extracted and processed, lignin has a wide variety of uses and applications, including opportunities to displace traditional fossil- based chemicals and products. lignin-derived products will play a crucial role in the canadian bio-economy value chain.

nextfor, a program of the centre for research and innovation in the bio-economy (cribe) is launching a new accelerated request for proposals (rfp) from standing or newly established consortiums which have commercial or pre-commercial ready technologies and solutions to establish or increase the commercial readiness of one of the lignin based platforms as identified by nextfor’s high performance lignin forums:

• polymer fine chemicals;
• resins/adhesives;
• thermoplastics and composites

to be eligible for this challenge, the proposed products and/or applications must utilize wood-based lignin.